<DOC>
	<DOCNO>NCT00084227</DOCNO>
	<brief_summary>The primary objective confirm hypothesis azithromycin plus chloroquine non-inferior atovaquone-proguanil treatment symptomatic , uncomplicated malaria due P. falciparum .</brief_summary>
	<brief_title>Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<mesh_term>Atovaquone , proguanil drug combination</mesh_term>
	<criteria>Written inform consent subject legally authorize representative Females male &gt; = 18 year age uncomplicated , symptomatic malaria indicate presence following : . ) Blood smear positive Plasmodium falciparum asexual parasitemia 1000 40,000 parasites/mL ; b . ) Fever history fever ( &gt; = 38.5 C/101.2 F rectal tympanic ; &gt; = 37.5 C/99.5 F axillary &gt; = 38 C/100.4 F oral ) within prior 24 hour Serum glucose &gt; = 60 mg/dL ( fingerstick peripheral blood collection ) Positive rapid diagnostic test ( Binax NOW ICT ) positive P. falciparum Subjects must willing treated inpatient set minimum three day parasitemia clear Investigator deems subject fit discharge Women childbearing potential ( , woman surgically sterilize clearly postmenopausal ) , must negative urine gonadotropin prior entry study must agree use adequate contraception entire study one month last study visit Severe complicate malaria include subject follow : . ) Impaired consciousness ( e.g . obtundation , unarousable coma , delirium , stupor ) , seizure ( seizure within 24 hour prior enrollment ) abnormal neurologic exam suggestive severe complicate malaria b . ) Hemoglobinuria c. ) Jaundice d. ) Respiratory distress ( respiratory rate â‰¥ 30 breaths/minute ) e. ) Persistent vomit f. ) Hematuria , report patient Pregnant breastfeed woman History allergy hypersensitivity azithromycin macrolide , atovaquone , proguanil chloroquine Concomitant administration rifampin rifabutin metoclopramide History epilepsy psoriasis History treatment antimalarial drug ( chloroquine , quinine , mefloquine , atovaquone/proguanil , sulfadoxine/pyrimethamine , artemisinin compound ) antibacterial know antimalarial activity ( macrolides , doxycycline , clindamycin ) within 2 week prior enrollment study Known suspect cardiovascular , hepatic renal abnormality opinion Investigator would place subject increase risk participate study . The following finding specific exclusion : . ) Known suspect creatinine clearance &lt; 30 mL/min b . ) ALT and/or AST &gt; 3 x upper limit normal Inability swallow oral medication tablet capsule form Treatment investigational drug within 30 day prior enrollment study Alcohol and/or drug abuse Requirement use medication study might interfere evaluation study drug Specific systemic disease medical condition would interfere evaluation therapeutic response safety study drug Inability comprehend and/or unwillingness follow study protocol Prior participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>